Código QR

Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection

Background/Aims: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the p...

Descrición completa

Gardado en:
Principais autores: Nilay Danış, Hüseyin Toz, Nalan Ünal, Mümtaz Yılmaz, İlker Turan, Fulya Günşar, Zeki Karasu, Galip Ersöz, Mehmet Özkahya, Ulus Salih Akarca
Formato: Artigo
Idioma:Inglês
Publicado: Turkish Society of Gastroenterology 2019-08-01
Series:The Turkish Journal of Gastroenterology
Assuntos:
Paritaprevir
ritonavir
ombitasvir
dasabuvir
renal transplant
hepatitis C
Acceso en liña:https://turkjgastroenterol.org/index.php/tjg/article/view/3459
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares